Explore end-to-end solutions throughout development — from portfolio optimization and regulatory strategy, to Phase I-IV clinical trials, market access planning, and more.
See solutionsWHAT WE DO
HOW WE DO IT
Parexel Biotech provides the end-to-end capabilities you’ll need to succeed. We're fast, flexible, and dedicated to impacting patient lives.
Learn moreUtilize our expertise across therapeutic areas, combining innovative trial designs, leading clinical and regulatory expertise, global reach, and a passion for changing patient lives.
See expertiseTherapeutic Expertise
Cross-Therapeutic Expertise
Our experts help you stay at the forefront of the industry - and ahead of change.
See insightsNew Medicines, Novel Insights
Discussions on Diversity
The Regulatory Navigator
Thinking about joining a clinical trial? Learn the drug development process, what it’s like to participate, how to find a trial, and answers to frequently asked questions.
Learn moreINTERESTED IN PARTICIPATING?
HEAR FROM REAL PATIENTS
TRIAL SITES
Want to collaborate with us to offer clinical trials at your site? We would welcome the opportunity to discuss.
Learn moreWe are one of the largest CROs in the world, speeding life-changing medicine to market by engaging patients With Heart™. Learn about who we are, what we do, and what we believe.
About ParexelWhat can we help you find today?
RBQM calls for new ways of operating that will change the clinical development process. ICH E8 (R1) will guide revisions and alignments for the suite of ICH efficacy guidelines. Parexel’s RBQM experts Amy Kissam-Sands and Tim Audin, Senior Director, Global Biometrics Group Lead sat down with Taren Grom, Editor, PharmaVOICE to discuss the ICH E8 (R1) guidance, its impact on the industry and how we can fill the gaps.
